The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Curcumin and colorectal cancer: An update and current perspective on this natural medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, it has been demonstrated that curcumin can interfere with colon carcinogenesis in multiple chemical and genetic rodent models.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [149]
In the citing paper
“James Graham Brown Cancer Center initiated a phase I clinical trials to test the therapeutic effect of plant exosomes on colon cancer (NCT01294072) [149].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [149]
In the citing paper
“And, it has been revealed that curcumin has a potent inhibitory impact on the growth of colon cancer cell lines.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
Research works printed but not linked: 160
- Obrand, 1997, Incidence and patterns of recurrence following curative resection for colorectal carcinoma, Dis. Colon Rectum, 40, 15, 10.1007/BF02055676 · DOI
- O’Connell, 2008, Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set, J. Clin. Oncol., 26, 2336, 10.1200/JCO.2007.15.8261 · DOI
- Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J. Clin. Oncol., 27, 3109, 10.1200/JCO.2008.20.6771 · DOI
- Allen, 2019, Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development, Genome Med., 11, 11, 10.1186/s13073-019-0621-2 · DOI
- Farhana, 2018, Role of microbiome in carcinogenesis process and epigenetic regulation of colorectal cancer, Methods Mol. Biol., 1856, 35, 10.1007/978-1-4939-8751-1_3 · DOI
- Chen, 2018, The role of the gut microbiome in colorectal cancer, Clin. Colon Rectal Surg., 31, 192, 10.1055/s-0037-1602239 · DOI
- Bachmeier, 2018, The role of curcumin in prevention and management of metastatic disease, Int. J. Mol. Sci., 19, 10.3390/ijms19061716 · DOI
- Chikara, 2018, Oxidative stress and dietary phytochemicals: role in cancer chemoprevention and treatment, Cancer Lett., 413, 122, 10.1016/j.canlet.2017.11.002 · DOI
- Allegra, 2017, Anticancer activity of curcumin and its analogues: preclinical and clinical studies, Cancer Invest., 35, 1, 10.1080/07357907.2016.1247166 · DOI
- Goel, 2010, Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs, Nutr. Cancer, 62, 919, 10.1080/01635581.2010.509835 · DOI
- Goel, 2008, Multi-targeted therapy by curcumin: how spicy is it?, Mol. Nutr. Food Res., 52, 1010, 10.1002/mnfr.200700354 · DOI
- Goel, 2008, Curcumin as “Curecumin”: from kitchen to clinic, Biochem. Pharmacol., 75, 787, 10.1016/j.bcp.2007.08.016 · DOI
- Link, 2013, Curcumin modulates DNA methylation in colorectal cancer cells, PLoS One, 8, 10.1371/journal.pone.0057709 · DOI
- Ravindranathan, 2018, A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer, Sci. Rep., 8, 13869, 10.1038/s41598-018-32267-8 · DOI
- Shakibaei, 2014, Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures, PLoS One, 9, 10.1371/journal.pone.0085397 · DOI
- Shakibaei, 2015, Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer, BMC Cancer, 15, 250, 10.1186/s12885-015-1291-0 · DOI
- Shakibaei, 2013, Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways, PLoS One, 8, 10.1371/journal.pone.0057218 · DOI
- Toden, 2015, Novel evidence for curcumin and boswellic acid-induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer, Cancer Prev. Res. (Phila), 8, 431, 10.1158/1940-6207.CAPR-14-0354 · DOI
- Toden, 2015, Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer, Carcinogenesis, 36, 355, 10.1093/carcin/bgv006 · DOI
- Willenbacher, 2019, Curcumin: new insights into an ancient ingredient against cancer, Int. J. Mol. Sci., 20, 10.3390/ijms20081808 · DOI
- Hu, 2017, Curcumin in hepatobiliary disease: pharmacotherapeutic properties and emerging potential clinical applications, Ann. Hepatol., 16, 835, 10.5604/01.3001.0010.5273 · DOI
- Goncalves, 2019, Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD), Eur. J. Med. Chem., 163, 911, 10.1016/j.ejmech.2018.12.020 · DOI
- Khan, 2019, Mechanistic insights of hepatoprotective effects of curcumin: therapeutic updates and future prospects, Food Chem. Toxicol., 124, 182, 10.1016/j.fct.2018.12.002 · DOI
- Chen, 2018, The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway, Int. J. Mol. Sci., 19, 10.3390/ijms19092729 · DOI
- Chandran, 2012, A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis, Phytother. Res., 26, 1719, 10.1002/ptr.4639 · DOI
- Sanmukhani, 2014, Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial, Phytother. Res., 28, 579, 10.1002/ptr.5025 · DOI
- Eke-Okoro, 2018, Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia, J. Clin. Pharm. Ther., 43, 460, 10.1111/jcpt.12703 · DOI
- Naeini, 2019, Antitumor effects of curcumin: a lipid perspective, J. Cell. Physiol., 10.1002/jcp.28262 · DOI
- Mirzaei, 2018, MicroRNA: a novel target of curcumin in cancer therapy, J. Cell. Physiol., 233, 3004, 10.1002/jcp.26055 · DOI · Paper page
- Carlos-Reyes, 2019, Dietary compounds as epigenetic modulating agents in cancer, Front. Genet., 10, 79, 10.3389/fgene.2019.00079 · DOI
- Bahrami, 2017, Therapeutic potential of targeting Wnt/beta-catenin pathway in treatment of colorectal cancer: rational and progress, J. Cell. Biochem., 118, 1979, 10.1002/jcb.25903 · DOI
- Salehi, 2019, The therapeutic potential of curcumin: a review of clinical trials, Eur. J. Med. Chem., 163, 527, 10.1016/j.ejmech.2018.12.016 · DOI
- Cani, 2018, Human gut microbiome: hopes, threats and promises, Gut, 67, 1716, 10.1136/gutjnl-2018-316723 · DOI · Paper page
- Rajagopala, 2017, The human microbiome and Cancer, Cancer Prev. Res. (Phila), 10, 226, 10.1158/1940-6207.CAPR-16-0249 · DOI
- Chen, 2019, Effects of intestinal microbial(-)elaborated butyrate on oncogenic signaling pathways, Nutrients, 11, 10.3390/nu11051026 · DOI
- Chung, 2018, Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells, Cell Host Microbe, 23, 203, 10.1016/j.chom.2018.01.007 · DOI
- Zhang, 2018, Association between Fusobacterium nucleatum and colorectal cancer: progress and future directions, J. Cancer, 9, 1652, 10.7150/jca.24048 · DOI
- Yang, 2017, Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear Factor-kappaB, and up-regulating expression of MicroRNA-21, Gastroenterology, 152, 851, 10.1053/j.gastro.2016.11.018 · DOI
- Brennan, 2019, Fusobacterium nucleatum – symbiont, opportunist and oncobacterium, Nat. Rev. Microbiol., 17, 156, 10.1038/s41579-018-0129-6 · DOI · Paper page
- Gholizadeh, 2017, Carcinogenesis mechanisms of Fusobacterium nucleatum, Biomed. Pharmacother., 89, 918, 10.1016/j.biopha.2017.02.102 · DOI
- Zhou, 2018, Fusobacterium and colorectal cancer, Front. Oncol., 8, 371, 10.3389/fonc.2018.00371 · DOI
- Ohno, 2017, Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells, PLoS One, 12, 10.1371/journal.pone.0185999 · DOI
- Peterson, 2018, Effects of turmeric and curcumin dietary supplementation on human gut microbiota: a double-blind, randomized, placebo-controlled pilot study, J. Evid. Based Integr. Med., 23, 10.1177/2515690X18790725 · DOI
- Mori, 2019, Gut microbiota analysis in postoperative lynch syndrome patients, Front. Microbiol., 10, 1746, 10.3389/fmicb.2019.01746 · DOI
- Youssef, 2018, Stool microbiota composition differs in patients with stomach, colon, and rectal neoplasms, Dig. Dis. Sci., 63, 2950, 10.1007/s10620-018-5190-5 · DOI
- Li, 2019, Intervention with alpha-ketoglutarate ameliorates colitis-related colorectal carcinoma via modulation of the gut microbiome, Biomed Res. Int., 2019
- McFadden, 2015, The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention, Inflamm. Bowel Dis., 21, 2483, 10.1097/MIB.0000000000000522 · DOI
- Burge, 2019, Curcumin and intestinal inflammatory diseases: molecular mechanisms of protection, Int. J. Mol. Sci., 20, 10.3390/ijms20081912 · DOI
- Takiishi, 2017, Intestinal barrier and gut microbiota: shaping our immune responses throughout life, Tissue Barriers, 5, 10.1080/21688370.2017.1373208 · DOI · Paper page
- Salvo Romero, 2015, The intestinal barrier function and its involvement in digestive disease, Rev. Esp. Enferm. Dig., 107, 686
- Wang, 2017, Curcumin improves intestinal barrier function: modulation of intracellular signaling, and organization of tight junctions, Am. J. Physiol. Cell Physiol., 312, C438, 10.1152/ajpcell.00235.2016 · DOI
- Wang, 2012, Curcumin ameliorates hydrogen peroxide-induced epithelial barrier disruption by upregulating heme oxygenase-1 expression in human intestinal epithelial cells, Dig. Dis. Sci., 57, 1792, 10.1007/s10620-012-2094-7 · DOI
- Ghosh, 2014, Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice--role of intestinal permeability and macrophage activation, PLoS One, 9, 10.1371/journal.pone.0108577 · DOI
- Li, 2014, Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy, World J. Gastroenterol., 20, 17699, 10.3748/wjg.v20.i47.17699 · DOI
- Yesudhas, 2014, Multiple roles of toll-like receptor 4 in colorectal cancer, Front. Immunol., 5, 334, 10.3389/fimmu.2014.00334 · DOI
- Zhu, 2014, Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway in experimental traumatic brain injury, J. Neuroinflammation, 11, 59, 10.1186/1742-2094-11-59 · DOI
- Fu, 2014, Curcumin attenuates inflammatory responses by suppressing TLR4-mediated NF-kappaB signaling pathway in lipopolysaccharide-induced mastitis in mice, Int. Immunopharmacol., 20, 54, 10.1016/j.intimp.2014.01.024 · DOI
- Jobin, 1999, Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity, J. Immunol., 163, 3474, 10.4049/jimmunol.163.6.3474 · DOI
- Moon, 2006, Curcumin decreases binding of Shiga-like toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: suppression of p38, JNK and NF-kappaB p65 as potential targets, Biol. Pharm. Bull., 29, 1470, 10.1248/bpb.29.1470 · DOI
- Shi, 2016, Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer, Gut, 65, 1470, 10.1136/gutjnl-2014-308455 · DOI
- Schaefer, 2015, MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis, BMC Immunol., 16, 5, 10.1186/s12865-015-0069-0 · DOI
- Thorlacius-Ussing, 2017, Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with inflammatory bowel disease, Inflamm. Bowel Dis., 23, 739, 10.1097/MIB.0000000000001086 · DOI
- Mudduluru, 2011, Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer, Biosci. Rep., 31, 185, 10.1042/BSR20100065 · DOI · Paper page
- Cherukuri, 2014, Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice, Mol. Oncol., 8, 169, 10.1016/j.molonc.2013.10.009 · DOI
- Xiang, 2012, Expression of BMP2, TLR3, TLR4 and COX2 in colorectal polyps, adenoma and adenocarcinoma, Mol. Med. Rep., 6, 973, 10.3892/mmr.2012.1046 · DOI
- Cox, 2004, Colorectal cancer study, polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer, Br. J. Cancer, 91, 339, 10.1038/sj.bjc.6601906 · DOI
- Goel, 2001, Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells, Cancer Lett., 172, 111, 10.1016/S0304-3835(01)00655-3 · DOI
- Plummer, 1999, Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex, Oncogene, 18, 6013, 10.1038/sj.onc.1202980 · DOI
- Villegas, 2011, Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice, Mol. Nutr. Food Res., 55, 259, 10.1002/mnfr.201000225 · DOI
- Kubota, 2012, Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice, Nutr. Cancer, 64, 72, 10.1080/01635581.2012.630554 · DOI
- Zhong, 2018, The role of tumor-associated macrophages in colorectal carcinoma progression, Cell. Physiol. Biochem., 45, 356, 10.1159/000486816 · DOI
- Norton, 2015, Immune cell interplay in colorectal cancer prognosis, World J. Gastrointest. Oncol., 7, 221, 10.4251/wjgo.v7.i10.221 · DOI
- Gao, 2015, Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13, J. Mol. Cell. Cardiol., 85, 131, 10.1016/j.yjmcc.2015.04.025 · DOI
- Zhou, 2015, Curcumin modulates macrophage polarization through the inhibition of the toll-like receptor 4 expression and its signaling pathways, Cell. Physiol. Biochem., 36, 631, 10.1159/000430126 · DOI
- Mohammadi, 2019, Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent, J. Nutr. Biochem., 66, 1, 10.1016/j.jnutbio.2018.12.005 · DOI
- Xu, 2017, Curcumin up regulates T helper 1 cells in patients with colon cancer, Am. J. Transl. Res., 9, 1866
- Rahimi, 2019, Targeting the balance of T helper cell responses by curcumin in inflammatory and autoimmune states, Autoimmun. Rev., 18, 738, 10.1016/j.autrev.2019.05.012 · DOI
- Shafabakhsh, 2019, Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy, Pharmacol. Res., 147, 10.1016/j.phrs.2019.104353 · DOI
- Burada, 2015, Autophagy in colorectal cancer: an important switch from physiology to pathology, World J. Gastrointest. Oncol., 7, 271, 10.4251/wjgo.v7.i11.271 · DOI
- Chen, 2019, Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy, Mol. Cancer, 18, 101, 10.1186/s12943-019-1030-2 · DOI
- Udristioiu, 2019, Autophagy dysfunctions associated with cancer cells and their therapeutic implications, Biomed. Pharmacother., 115, 10.1016/j.biopha.2019.108892 · DOI
- Condello, 2019, Targeting autophagy to overcome human diseases, Int. J. Mol. Sci., 20, 10.3390/ijms20030725 · DOI
- Liu, 2019, Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells, Arch. Gynecol. Obstet., 299, 1627, 10.1007/s00404-019-05058-3 · DOI
- Liu, 2018, Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway, Oncol. Rep., 39, 1523
- White, 2016, Autophagy and p53, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a026120 · DOI
- He, 2011, Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin, Cancer Invest., 29, 208, 10.3109/07357907.2010.550592 · DOI
- Sun, 2019, Alpha-hederin induces autophagic cell death in colorectal cancer cells through reactive oxygen species dependent AMPK/mTOR signaling pathway activation, Int. J. Oncol., 54, 1601
- Sun, 2017, AMP-activated protein kinase: a therapeutic target in intestinal diseases, Open Biol., 7, 10.1098/rsob.170104 · DOI
- Song, 2014, Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer, Cell Death Dis., 5, e1504, 10.1038/cddis.2014.463 · DOI
- Thent, 2017, Is metformin a therapeutic paradigm for colorectal cancer: insight into the molecular pathway?, Curr. Drug Targets, 18, 734, 10.2174/1389450118666161205125548 · DOI
- Liu, 2017, Curcumin activates AMPK pathway and regulates lipid metabolism in rats following prolonged clozapine exposure, Front. Neurosci., 11, 558, 10.3389/fnins.2017.00558 · DOI
- Zhu, 2018, Cancer stem cells and tumorigenesis, Biophys. Rep., 4, 178, 10.1007/s41048-018-0062-2 · DOI
- Munro, 2018, Cancer stem cells in colorectal cancer: a review, J. Clin. Pathol., 71, 110, 10.1136/jclinpath-2017-204739 · DOI
- Visvader, 2012, Cancer stem cells: current status and evolving complexities, Cell Stem Cell, 10, 717, 10.1016/j.stem.2012.05.007 · DOI
- Boman, 2004, Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population, Am. J. Pathol., 165, 1489, 10.1016/S0002-9440(10)63407-4 · DOI
- Nautiyal, 2011, Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells, J. Mol. Signal., 6, 7, 10.1186/1750-2187-6-7 · DOI
- Huang, 2016, Curcumin induces apoptosis of colorectal cancer stem cells by coupling with CD44 marker, J. Agric. Food Chem., 64, 2247, 10.1021/acs.jafc.5b05649 · DOI
- Buhrmann, 2014, Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT, PLoS One, 9, 10.1371/journal.pone.0107514 · DOI
- Ramasamy, 2015, Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy, Cancer Cell Int., 15, 96, 10.1186/s12935-015-0241-x · DOI
- Kagohara, 2018, Epigenetic regulation of gene expression in cancer: techniques, resources and analysis, Brief. Funct. Genomics, 17, 49, 10.1093/bfgp/elx018 · DOI
- Esteller, 2008, Epigenetics in cancer, N. Engl. J. Med., 358, 1148, 10.1056/NEJMra072067 · DOI
- Guo, 2015, Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1, Biochem. Pharmacol., 94, 69, 10.1016/j.bcp.2015.01.009 · DOI
- Jiang, 2015, Curcumin reactivates silenced tumor suppressor gene RARbeta by reducing DNA methylation, Phytother. Res., 29, 1237, 10.1002/ptr.5373 · DOI
- Chatterjee, 2019, Curcumin-mediated demethylation of the proximal promoter CpG island enhances the KLF4 recruitment that leads to increased expression of p21Cip1 in vitro, J. Cell. Biochem., 120, 809, 10.1002/jcb.27442 · DOI
- Guo, 2018, DNA methylome and transcriptome alterations and cancer prevention by curcumin in colitis-accelerated colon cancer in mice, Carcinogenesis, 39, 669, 10.1093/carcin/bgy043 · DOI
- Singh, 2017, Histone deacetylase inhibitors for the treatment of colorectal cancer: recent progress and future prospects, Curr. Cancer Drug Targets, 17, 456, 10.2174/1568009617666170109150134 · DOI
- Bora-Tatar, 2009, Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies, Bioorg. Med. Chem., 17, 5219, 10.1016/j.bmc.2009.05.042 · DOI
- Chen, 2013, Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases, Carcinogenesis, 34, 1442, 10.1093/carcin/bgt070 · DOI
- Chen, 2007, Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells, Basic Clin. Pharmacol. Toxicol., 101, 427, 10.1111/j.1742-7843.2007.00142.x · DOI
- Hu, 2009, Curcumin-induced histone acetylation in malignant hematologic cells, J. Huazhong Univ. Sci. Technol. Med. Sci., 29, 25, 10.1007/s11596-009-0105-5 · DOI
- Gandhy, 2012, Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs, BMC Cancer, 12, 564, 10.1186/1471-2407-12-564 · DOI
- Carroll, 2011, Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia, Cancer Prev. Res. (Phila), 4, 354, 10.1158/1940-6207.CAPR-10-0098 · DOI
- Cruz-Correa, 2018, Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis, Gastroenterology, 155, 668, 10.1053/j.gastro.2018.05.031 · DOI
- Cruz-Correa, 2006, Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis, Clin. Gastroenterol. Hepatol., 4, 1035, 10.1016/j.cgh.2006.03.020 · DOI
- Sharma, 2004, Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance, Clin. Cancer Res., 10, 6847, 10.1158/1078-0432.CCR-04-0744 · DOI
- Sharma, 2001, Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer, Clin. Cancer Res., 7, 1894
- James, 2015, Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy, Cancer Lett., 364, 135, 10.1016/j.canlet.2015.05.005 · DOI
- Liao, 2018, Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma, Arch. Oral Biol., 92, 32, 10.1016/j.archoralbio.2018.04.015 · DOI
- Zou, 2018, Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer, J. Cell. Biochem., 119, 1420, 10.1002/jcb.26302 · DOI
- Liu, 2016, Oral bioavailability of curcumin: problems and advancements, J. Drug Target, 24, 694, 10.3109/1061186X.2016.1157883 · DOI
- Toden, 2017, The holy grail of curcumin and its efficacy in various diseases: is bioavailability truly a big concern?, J. Restor. Med., 6, 27, 10.14200/jrm.2017.6.0101 · DOI
- Jayaprakasha, 2016, Enhanced colon cancer chemoprevention of curcumin by nanoencapsulation with whey protein, Eur. J. Pharmacol., 789, 291, 10.1016/j.ejphar.2016.07.017 · DOI
- Chaurasia, 2016, Curcumin-polymeric nanoparticles against colon-26 tumor-bearing mice: cytotoxicity, pharmacokinetic and anticancer efficacy studies, Drug Dev. Ind. Pharm., 42, 694, 10.3109/03639045.2015.1064941 · DOI
- Yogosawa, 2012, Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells, J. Nat. Prod., 75, 2088, 10.1021/np300465f · DOI
- Cuomo, 2011, Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation, J. Nat. Prod., 74, 664, 10.1021/np1007262 · DOI
- Howells, 2011, Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo, Int. J. Cancer, 129, 476, 10.1002/ijc.25670 · DOI
- Ghoneim, 2009, Effects of curcumin on ethanol-induced hepatocyte necrosis and apoptosis: implication of lipid peroxidation and cytochrome c, Naunyn Schmiedebergs Arch. Pharmacol., 379, 47, 10.1007/s00210-008-0335-2 · DOI
- Jiao, 2009, Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator, Blood, 113, 462, 10.1182/blood-2008-05-155952 · DOI · Paper page
- Zhang, 2018, Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT8/5Fu human colorectal cancer cell line, Mol. Med. Rep., 18, 5409
- Zhu, 2018, Curcumin induces autophagy via inhibition of yes-associated protein (YAP) in human colon cancer cells, Med. Sci. Monit., 24, 7035, 10.12659/MSM.910650 · DOI
- Su, 2018, Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells, Int. J. Oncol., 53, 1343
- Lee, 2018, Curcumin suppresses oncogenicity of human colon cancer cells by covalently modifying the cysteine 67 residue of SIRT1, Cancer Lett., 431, 219, 10.1016/j.canlet.2018.05.036 · DOI
- Huang, 2017, Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway, Oncotarget, 8, 40264, 10.18632/oncotarget.16828 · DOI
- Tong, 2016, Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-kappaB, uPA activator and MMP9, Oncol. Lett., 12, 4139, 10.3892/ol.2016.5148 · DOI
- Adeyeni, 2016, BMI1 is downregulated by the natural compound curcumin, but not by bisdemethoxycurcumin and dimethoxycurcumin, Physiol. Rep., 4, 10.14814/phy2.12906 · DOI
- Ruiz de Porras, 2016, Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-kappaB signalling pathway, Sci. Rep., 6, 24675, 10.1038/srep24675 · DOI
- Zhang, 2016, Curcumin inhibits tumor epithelialmesenchymal transition by downregulating the Wnt signaling pathway and upregulating NKD2 expression in colon cancer cells, Oncol. Rep., 35, 2615, 10.3892/or.2016.4669 · DOI
- Guo, 2015, Curcumin combined with oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis, Phytother. Res., 29, 357, 10.1002/ptr.5257 · DOI
- Wang, 2015, Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro, Anticancer Drugs, 26, 15, 10.1097/CAD.0000000000000132 · DOI
- Jiang, 2014, PI3K/Akt pathway involving into apoptosis and invasion in human colon cancer cells LoVo, Mol. Biol. Rep., 41, 3359, 10.1007/s11033-014-3198-2 · DOI
- Chen, 2013, Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer, Evid. Complement. Alternat. Med., 2013
- Shehzad, 2013, Curcumin induces apoptosis in human colorectal carcinoma (HCT-15) cells by regulating expression of Prp4 and p53, Mol. Cells, 35, 526, 10.1007/s10059-013-0038-5 · DOI
- Blakemore, 2013, Curcumin-induced mitotic arrest is characterized by spindle abnormalities, defects in chromosomal congression and DNA damage, Carcinogenesis, 34, 351, 10.1093/carcin/bgs345 · DOI
- Lu, 2011, Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells, Mol. Cell. Biochem., 354, 247, 10.1007/s11010-011-0824-3 · DOI
- Watson, 2010, Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells, Cancer Lett., 297, 1, 10.1016/j.canlet.2010.04.018 · DOI
- Patel, 2008, Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R, Int. J. Cancer, 122, 267, 10.1002/ijc.23097 · DOI
- Sandur, 2009, Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity, Int. J. Radiat. Oncol. Biol. Phys., 75, 534, 10.1016/j.ijrobp.2009.06.034 · DOI
- Johnson, 2009, Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling, Anticancer Res., 29, 3185
- Kunnumakkara, 2009, Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model, Int. J. Cancer, 125, 2187, 10.1002/ijc.24593 · DOI
- Milacic, 2008, Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo, Cancer Res., 68, 7283, 10.1158/0008-5472.CAN-07-6246 · DOI
- Kunnumakkara, 2008, Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products, Clin. Cancer Res., 14, 2128, 10.1158/1078-0432.CCR-07-4722 · DOI
- Yin, 2019, Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-beta/Smad2/3 signaling pathway, Onco Targets Ther., 12, 3893, 10.2147/OTT.S199601 · DOI
- Irving, 2015, Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial, Trials, 16, 110, 10.1186/s13063-015-0641-1 · DOI
- Wu, 2017, Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside, Biochim. Biophys. Acta Rev. Cancer, 1868, 538, 10.1016/j.bbcan.2017.10.001 · DOI
- Siddiqui, 2009, Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice, Br. J. Nutr., 102, 967, 10.1017/S0007114509345250 · DOI
- Adachi, 2020, Theracurmin inhibits intestinal polyp development in Apc-mutant mice by inhibiting inflammation-related factors, Cancer Sci., 10.1111/cas.14329 · DOI
- Greil, 2018, A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc TM) in patients with locally advanced or metastatic cancer, Cancer Chemother. Pharmacol., 82, 695, 10.1007/s00280-018-3654-0 · DOI
- Li, 2007, Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer, Mol. Cancer Ther., 6, 1276, 10.1158/1535-7163.MCT-06-0556 · DOI
- Moradi-Marjaneh, 2018, Phytosomal curcumin elicits anti-tumor properties through suppression of angiogenesis, cell proliferation and induction of oxidative stress in colorectal cancer, Curr. Pharm. Des., 24, 4626, 10.2174/1381612825666190110145151 · DOI
- Lotfi-Attari, 2017, Co-delivery of curcumin and chrysin by polymeric nanoparticles inhibit synergistically growth and hTERT gene expression in human colorectal cancer cells, Nutr. Cancer, 69, 1290, 10.1080/01635581.2017.1367932 · DOI
Cited by
Sorted by citations
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Chen, L., Yang, F., Chen, S., & Tai, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995882 · Cited by 60
Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70294 · Cited by 5
Metadata
- Authors
- Weng, W., & Goel, A.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 80
- Pages
- 73-86
- ISSN
- 1044-579X
- PMC
- PMC7438305
- Cited by
- 287
- References
- 8
- Language
- en
- Funders
- National Cancer Institute, National Institutes of Health (R01 CA72851, CA181572, CA184792, CA202797, U01 CA187956)
- Baylor Sammons Cancer Center and Foundation
- Baylor Scott & White Research Institute
- Beckman Research Institute of City of Hope
- National Natural Science Foundation of China (81672826, 81874179)
- Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ044)
- Shanghai Pujiang Talent Plan (18PJD047)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review